Zepp Health reported Q2 2026 revenue of $63.5M, up 6.9% year-over-year, driven by new product launches and improved product mix. Gross margin improved to 37.4%, but net loss widened to $11.3M due to foreign exchange headwinds and increased spending on R&D and marketing. The company launched new wearable products and plans to raise prices on its Bip family in 2027 to improve unit economics. For Q3 2026, Zepp expects revenue between $68M and $73M, reflecting ongoing supply recovery and product ramp-up.
Alumis' stock dropped 56.58% after its Phase II lupus drug trial failed to meet main goals, causing a significant market reaction. However, positive results in a subgroup of lupus patients with a high interferon gene signature offer a potential path ...
Alumis Inc. shares dropped 56.76% after its Phase 2b trial for a lupus drug failed to meet key goals, though some patient groups showed promise. Enovis Corporation shares fell 16.51% following its announcement to acquire eCential Robotics for €155 mi...
SPAC stocks like Rising Dragon Acquisition surged nearly 47% amid volatility, while biotech firm bioAffinity Technologies jumped 44% after a reverse stock split. Renewable energy company Fervo Energy gained 28% following a major geothermal power deal...
Vault Strategic Mining Corp has updated the terms of its non-brokered private placement, now offering up to 12 million units at $0.125 each, aiming to raise $1.5 million. Each unit includes one common share and one warrant exercisable at $0.20 within...
Enovis has lowered its price target to $27 from $30 following its binding offer to acquire eCential Robotics for €155 million. This acquisition aims to strengthen Enovis's position in surgical robotics and enhance its ASTRA technology ecosystem. Desp...
